NL-OMON49110已完成不适用
Early prediction of adalimumab levels with InsightRx - Early prediction of adalimumab levels with InsightRx
Maxima Medisch Centrum0 个研究点目标入组 40 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •All adult patients over 18 years of age with new adalimumab prescriptions at
- •initial dosing interval of 14 days for rheumatic diseases (RA,PsA,SpA) or
- •inflammatory bowel disease (UC, Crohn*s disease) will be eligible to
- •participate in our study.
排除标准
- •* Pregnancy
- •* Previous adalimumab use
- •* Allergy for adalimumab or excipients (Humira)
- •* Patients unable or unwilling to consent to participation to this trial
研究者
相似试验
进行中（未招募）
1 期
Rapidity of response to adalimumab treatment in patients with Crohn´s Disease.Crohn's diseaseMedDRA version: 16.1Level: PTClassification code 10011401Term: Crohn's diseaseSystem Organ Class: 10017947 - Gastrointestinal disordersEUCTR2013-004781-34-ESAbbVie Farmacéutica S.L.U.100
已完成
2 期
Evaluating the effects of Adalimumab in patients with acute respiratory distress syndrome caused by COVID-19IRCT20151227025726N23Shahid Beheshti University of Medical Sciences60
已完成
2 期
Adalimumab effectiveness in COVID-19COVID-19.C0VID-19U07.1IRCT20150303021315N22Tehran University of Medical Sciences40
已完成
不适用
Vroege voorspelling adalimumab spiegels met InsightRxInflammatory Bowel Diseases (M.Crohn and Ulcerative Colitis) and Rheumatic diseases (Rheumatoid Arthritis, Psoriatic Arthritis, Spondyloarthropathy)NL-OMON24282Máxima Medisch Centrum40
已完成
不适用
Prediction of Treatment Response at 6 Months by Combinatorial Analysis of Serum Biomarkers in Biotherapy Naive SpASpondylitis, AnkylosingNCT03561649University Hospital, Grenoble50